PIN1 and cancer: Consequently, BRCAness (similar to BRCA1 or BRCA2 gene mutation signatures) in cancer cells has been established to be associated with the inactivation of Pin1, which is essential for PARP inhibitor treatment, as it sensitizes cells (39).